U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07937852) titled 'A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)' on Nov. 10.
Brief Summary: The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).
Study Start Date: Jan. 18, 2027
Study Type: INTERVENTIONAL
Condition:
Multiple Sclerosis
Intervention:
DRUG: Fenebrutinib
Fenebrutinib will be administered as pe...